Clinical Trials Logo

Gluten-Sensitive Enteropathy clinical trials

View clinical trials related to Gluten-Sensitive Enteropathy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02895438 Completed - Diet, Gluten-Free Clinical Trials

Non Coeliac Gluten Sensitivity in Children

Start date: May 27, 2015
Phase: N/A
Study type: Interventional

Irritable Bowel syndrome (IBS) is a very frequent condition in children. Its management is difficult, often resulting in a persistence of chronical abdominal pain. In adults, many patients affected by IBS improve under a gluten-free diet, even in the absence of Celiac Disease (CD) or wheat allergy. This condition is called Non Coeliac Gluten Sensitivity (NCGS). However, it is still not clear how to diagnose and manage NCGS, and the pathophysiological mechanisms also remain elusive. The aim of this study is to determine if NCGS exists in children with IBS and to identify the clinical, serological, and histological characteristics, which could distinguish patients with NCGS from conventional IBS and CD patients. This is a prospective cohort study in a population of children affected by a moderate to severe IBS for more than 6 months. All children had a Gluten Free Diet (GFD) for 6 weeks. Then, children who improved under GFD were randomized in two groups for a double-blind placebo-controled trial. One group had a reintroduction of gluten followed by a wash-out period, then a placebo reintroduction, whereas the other group had the placebo first, then the wash-out and the gluten reintroduction.

NCT ID: NCT01893775 Completed - Celiac Disease Clinical Trials

Antibody Treatment for Advanced Celiac Disease

Start date: June 12, 2013
Phase: Phase 1
Study type: Interventional

Background: - Celiac disease is a condition where the immune system attacks the cells of the small intestine. The intestine becomes inflamed and cannot digest food properly. The disease most often causes a reaction to foods that contain gluten. Most people can treat celiac disease with a gluten-free diet. However, some people have digestion problems even on a gluten-free diet. Researchers want to try a new antibody therapy for celiac disease. The treatment may block the immune reaction that causes the disease. They will test this antibody in people who have celiac disease that has not responded to a gluten-free diet. Objectives: - To see if antibody therapy is a safe and effective treatment for celiac disease that has not responded to standard treatments. Eligibility: - Individuals at least 18 years of age who have been on a gluten-free diet for 6 to 12 months but still have symptoms of celiac disease. Design: - Participants will be screened with a physical exam and medical history. Blood samples will be collected. These samples will help determine if the specific antibody treatment is likely to work. - Before the start of the study, participants will have a biopsy of the small intestine. - Participants will receive three doses of the study antibody as injections. These doses will be given 3 weeks apart. - Treatment will be monitored with blood tests and heart function tests. Participants will also have a second small intestine biopsy within a week after the last dose of the antibody.